D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER

Authors

  • Sammeen Salim Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Asif Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Rabia Ahmed Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
  • Muhammad Tahir Khadim Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS) Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v71i1.3128

Keywords:

Invasive breast cancer, Programmed cell death protein 1, Programmed death-ligand 1

Abstract

Objective: To investigate the immunohistochemical expression of PD-1 and PD-L1 in breast cancer cases and its
correlation with clinicopathological factors.

Study Design: Cross sectional study.

Place and Duration of Study: Histopathology department, Armed Forces Institute of Pathology Rawalpindi, form Jan to Jun 2019.

Methodology: Sixty five cases of breast cancer were retrieved. Clinicopathological parameters like age, gender,
tumor grade and receptor status were noted. Immunohistochemistry for PD-1 and PD-L1 was applied. The data
was entered and statistical analysis was done using SPSS version 21. The associations between variables were
found using the Fisher exact test.

Results: Sixty five cases of breast cancer were investigated from tumour registry. The sample included female
patients, having mean age of 50.86 ± 11.1 Years. Invasive mammary (ductal) carcinoma, NST was the most prevalent subtype 60 (92.3%) and most tumors were grade I/II 53(82%). PD-1 expression was seen in TIL’s 31 (48%) and PD-L1 expression was observed in tumour cells 30 (46%). Expression of PD-1/PD-L1 expression was more common in premenopausal age group and grade I/II tumors. Among molecular subtypes, PD-L1 expression was detected in 11 (52%) TNBC, 5 (71%) in HR-/HER2+ and 12 (32)% in HR + HER2 - and PD-1 expression was observed in 13 (62%) TNBC, 5 (71%) in HR-/HER2+ and 13 (35%) in HR+ HER2-.

Conclusion: A large proportion of breast cancer cases show expression of PD-1 / PD-L1. Anti PD-1 and PD-L1
therapy may benefit these patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

23-02-2021

How to Cite

1.
Salim S, Asif M, Ahmed R, Khadim MT. D-1 / PD-L1 EXPRESSION IN INVASIVE BREAST CARCINOMA / CANCER. Pak Armed Forces Med J [Internet]. 2021 Feb. 23 [cited 2024 May 25];71(1):67-72. Available from: https://pafmj.org/PAFMJ/article/view/3128

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 4 5 6 > >>